Impact of SGLT2 inhibitors in patients with Fabry disease - PubMed
2 days ago
- #Fabry disease
- #Cardiac function
- #SGLT2 inhibitors
- SGLT2 inhibitors (SGLT2i) were studied in patients with Fabry disease (FD), a condition affecting the heart and kidneys.
- The study involved 48 patients (12 females) on FD-specific therapy, with advanced cardiac manifestations, including left ventricular hypertrophy (LVH).
- Males had significantly lower left ventricular ejection fraction (LVEF) compared to females at baseline.
- No treatment-related adverse events or Fabry-associated clinical events (FACEs) were reported during the study.
- Females showed a stable disease course regardless of SGLT2i treatment.
- Males experienced a slower decline in estimated glomerular filtration rate (eGFR) after SGLT2i initiation (from 3.7 to 2.7 ml/min/1.73 m² per year).
- A slight but significant improvement in LVEF (0.6% per year) was observed, particularly in males with reduced LVEF (<50%) at baseline.
- SGLT2i treatment was found to be safe in FD patients, with potential benefits for males with reduced LVEF.